IMMU-132, an SN-38 antibody-drug conjugate (ADC) targeting Trop-2, as a novel platform for the therapy of diverse metastatic solid cancers: Clinical results.

被引：0
|
作者：
Starodub, Alexander
Ocean, Allyson J.
Guarino, Michael J.
Picozzi, Vincent J.
Thomas, Salim Samuel
Messersmith, Wells A.
Shah, Manlsh A.
Vandat, Linda T.
Chuang, Ellen
Lin, Bruce S.
Govindan, Serengulam V.
Maliakal, Pius P.
Wegener, William A.
Hamburger, Steven A.
Sharkey, Robert M.
Goldenberg, David M.
机构：
[1] Indiana Univ, Hlth Goshen Ctr Canc Care, Goshen, IN USA
[2] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA
[3] Christiana Care Hlth Syst, Helen F Graham Canc Ctr, Newark, DE USA
[4] Virginia Mason Med Ctr, Seattle, WA 98101 USA
[5] Univ Florida, Hlth Canc Ctr, Orlando Hlth, Orlando, FL USA
[6] Univ Colorado Denver, Div Med Oncol, Aurora, CO USA
[7] Weill Cornell Med Coll, New York, NY USA
[8] Immunomedics Inc, Morris Plains, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.3032
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3032
引用
收藏
页数：1
相关论文
共 44 条
  • [31] Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer
    Perrone, Emanuele
    Lopez, Salvatore
    Zeybek, Burak
    Bellone, Stefania
    Bonazzoli, Elena
    Pelligra, Silvia
    Zammataro, Luca
    Manzano, Aranzazu
    Manara, Paola
    Bianchi, Anna
    Buza, Natalia
    Tymon-Rosario, Joan
    Altwerger, Gary
    Han, Chanhee
    Menderes, Gulden
    Ratner, Elena
    Silasi, Dan-Arin
    Azodi, Masoud
    Hui, Pei
    Schwartz, Peter E.
    Scambia, Giovanni
    Santin, Alessandro D.
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [32] Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan
    Gray, Jhanelle E.
    Heist, Rebecca S.
    Starodub, Alexander N.
    Camidge, D. Ross
    Kio, Ebenezer A.
    Masters, Gregory A.
    Purcell, W. Thomas
    Guarino, Michael J.
    Misleh, Jamal
    Schneider, Charles J.
    Schneider, Bryan J.
    Ocean, Allyson
    Johnson, Tirrell
    Gandhi, Leena
    Kalinsky, Kevin
    Scheff, Ronald
    Messersmith, Wells A.
    Govindan, Serengulam V.
    Maliakal, Pius P.
    Mudenda, Boyd
    Wegener, William A.
    Sharkey, Robert M.
    Goldenberg, David M.
    CLINICAL CANCER RESEARCH, 2017, 23 (19) : 5711 - 5719
  • [33] Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2-wild-type Triple-Negative Breast Cancer
    Cardillo, Thomas M.
    Sharkey, Robert M.
    Rossi, Diane L.
    Arrojo, Roberto
    Mostafa, Ali A.
    Goldenberg, David M.
    CLINICAL CANCER RESEARCH, 2017, 23 (13) : 3405 - 3415
  • [34] Therapy of gastrointestinal malignancies with an anti-Trop-2-SN-38 antibody drug conjugate (ADC) (sacituzumab govitecan): Phase I/II clinical experience
    Starodub, Alexander
    Ocean, Allyson J.
    Messersmith, Wells A.
    Picozzi, Vincent J.
    Guarino, Michael J.
    Bardia, Aditya
    Thomas, Sajeve Samuel
    Berlin, Jordan
    Shah, Manish A.
    Maliakal, Pius P.
    Wegener, William A.
    Sharkey, Robert M.
    Wilhelm, Francois
    Goldenberg, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [35] Labetuzumab govitecan (IMMU-130), an anti-CEACAM5/SN-38 antibody-drug conjugate, is active in patients (pts) with heavily pretreated metastatic colorectal cancer (mCRC): phase II results
    Dotan, Efrat
    Cohen, Steven J.
    Starodub, Alexander N.
    Lieu, Christopher H.
    Messersmith, Wells A.
    Guarino, Michael J.
    Marshall, John L.
    Goldberg, Richard M.
    Hecht, J. Randolph
    Maliakal, Pius
    Wegener, William A.
    Sharkey, Robert M.
    Wilhelm, Francois
    Lee, Lucy
    Goldenberg, David M.
    Berlin, Jordan D.
    CANCER RESEARCH, 2016, 76
  • [36] ADCT-502, a novel pyrrolobenzodiazepine (PBD)-based antibody-drug conjugate (ADC) targeting low HER2-expressing solid cancers
    Zammarchi, F.
    Chivers, S.
    Williams, D. G.
    Adams, L.
    Mellinas-Gomez, M.
    Tyrer, P.
    Corbett, S.
    D'Hooge, F.
    Dissanayake, S.
    Sims, S.
    Havenith, K.
    Howard, P. W.
    Hartley, J. A.
    Van Berkel, P. H.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S28 - S28
  • [37] First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
    Starodub, Alexander N.
    Ocean, Allyson J.
    Shah, Manish A.
    Guarino, Michael J.
    Picozzi, Vincent J., Jr.
    Vahdat, Linda T.
    Thomas, Sajeve S.
    Govindan, Serengulam V.
    Maliakal, Pius P.
    Wegener, William A.
    Hamburger, Steven A.
    Sharkey, Robert M.
    Goldenberg, David M.
    CLINICAL CANCER RESEARCH, 2015, 21 (17) : 3870 - 3878
  • [38] DB-1305 (a Trop-2 targeted antibody-drug-conjugate [ADC]) in patients (pts) with advanced solid tumors: Preliminary clinical results from the phase (Ph) I/IIa study
    Marathe, O.
    Cheng, Y.
    Spira, A. I.
    Hamilton, E. P.
    Rubinstein, M. M.
    Dong, X.
    Li, L.
    Lv, D.
    Shi, J.
    Gabrail, N.
    Amin, H.
    Wu, C.
    Zhu, Z.
    Qiu, Y.
    Gu, V.
    Qiu, X.
    Shi, R.
    Liu, L.
    Miao, P.
    Ueno, N. T.
    ANNALS OF ONCOLOGY, 2023, 34 : S480 - S480
  • [39] Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers
    Jhaveri, K.
    Han, H.
    Dotan, E.
    Oh, D-Y.
    Ferrario, C.
    Tolcher, A.
    Lee, K-W.
    Liao, C-Y.
    Kang, Y-K.
    Kim, Y. H.
    Hamilton, E.
    Spira, A.
    Patel, N.
    Karapetis, C.
    Rha, S. Y.
    Boyken, L.
    Woolery, J.
    Bedard, P.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S749 - S750
  • [40] Results of a phase 1/2 study of MHB036C: A potential best-in-class TROP2 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in locally advanced or metastatic solid tumors
    Lu, Shun
    Zhang, Qingyuan
    Meng, Xiangjiao
    Sun, Yuping
    Xiong, Hui Hua
    Lv, Dongqing
    Wang, Xiaojia
    Wu, Lin
    Dong, Xiaorong
    Ji, Yuanyuan
    Ji, Yinghua
    Han, Liang
    Lei, Kaijian
    Jiang, Ou
    Zhao, Yanqiu
    Zhang, Zhen
    Shi, Junwei
    Cao, Guoqing
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345